A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

NCT05605522 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor reprioritization of active trials.

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Gastric Cancer
Ewing Sarcoma
NTSR1 Expressing Solid Tumours
Neuroendocrine Differentiated (NED) Prostate Cancer

Interventions

DRUG: [225]-FPI-2059
DRUG: [111In]-FPI-2058

Sponsor

3B Pharmaceuticals GmbH